P. Dayer

The paraoxonase‐1 pathway is not a major bioactivation pathway of clopidogrel in vitro

Y. Daali, P. Dayer, J. Desmeules, 2012, British journal of pharmacology.

[Pharmacology of tramadol].

P. Dayer, J. Desmeules, L. Collart, 1997, Drugs.

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

D. Hochstrasser, Y. Daali, P. Dayer, 2009, The Pharmacogenomics Journal.

Clinical pharmacology and rationale of analgesic combinations.

V. Rollason, P. Dayer, J. Desmeules, 2003, European journal of anaesthesiology. Supplement.

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone

D. Hochstrasser, Y. Daali, P. Dayer, 2010, British journal of pharmacology.

Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.

T. Kronbach, P. Dayer, U. Zanger, 1986, The Journal of biological chemistry.

Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: Influence of genetic status on behaviour of atenolol, bopindolol and metoprolol

T. Leemann, P. Dayer, J. Rosenthaler, 2004, European Journal of Clinical Pharmacology.

Geneva Cocktail for Cytochrome P450 and P-Glycoprotein Activity Assessment Using Dried Blood Spots

Y. Daali, P. Dayer, B. Walder, 2014, Clinical pharmacology and therapeutics.